Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Clin Cancer Res. 2011 Nov 23;18(4):1015–1027. doi: 10.1158/1078-0432.CCR-11-2189

Figure 5. MRE11 Deficiency Increases Sensitivity to PARP Inhibition.

Figure 5

(A) HCT116-PTEN+/+ and −/− cells were subjected to UV laser microirradiation, and stained for γH2AX (red) and MRE11 (green). DNA was stained with DAPI (blue). (B) PC3, DU145, and 22RV1 cells were subjected to UVLM as in panel (A). (C) Whole-cell lysates of DU145, PC3, and 22RV1 cells were analysed by Western blot using antibodies against MRE11, RAD50, or actin. (D) MRE11 mRNA levels were analysed by quantitative RT-PCR. (E) MRE11-deficient ATLD2 fibroblasts were treated with 1 μM PARPi (or DMSO) and cell proliferation was assessed over 8 days. ATLD2 fibroblasts expressing wild-type MRE11 (ATLD2-wtMRE11) or endonuclease-deficient MRE11 (ATLD2-mtMRE11) were also analysed.